CLLD7 rabbit pAb
ENT-A6535
Description
| REF | ENT-A6535 |
|---|---|
| Category | Antibody Polyclonal |
| Description | CLLD7 rabbit pAb |
| Source | Rabbit |
| Applications | WB;IHC;IF;ELISA |
| Reactivity | Human;Mouse |
| Reactivity | Human;Mouse |
| Dilution | Western Blot: 1/500 – 1/2000. Immunohistochemistry: 1/100 – 1/300. ELISA: 1/20000. Not yet tested in other applications. |
| Immunogen | The antiserum was produced against synthesized peptide derived from human RCBTB1. AA range:251-300 |
| Storage Stability | -20°C/1 year |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1 mg/ml |
| Observed Band KD | 58kD |
| Human Gene ID | 55213 |
| Human Swiss Prot Nº | Q8NDN9 |
| Subcellular Location | Nucleus . |
Other Name: RCBTB1; CLLD7; E4.5; RCC1 and BTB domain-containing protein 1; Chronic lymphocytic leukemia deletion region gene 7 protein; CLL deletion region gene 7 protein; Regulator of chromosome condensation and BTB domain-containing protein 1
Background: This gene encodes a protein with an N-terminal RCC1 domain and a C-terminal BTB (broad complex, tramtrack and bric-a-brac) domain. In rat, over-expression of this gene in vascular smooth muscle cells induced cellular hypertrophy. In rat, the C-terminus of RCBTB1 interacts with the angiotensin II receptor-1A. In humans, this gene maps to a region of chromosome 13q that is frequently deleted in B-cell chronic lymphocytic leukemia and other lymphoid malignancies. [provided by RefSeq, Jul 2008],
